Learn More About PENTASA® and Other Gastroenterology Products From Shire

To directly receive news and information updates about PENTASA and other gastroenterology products from Shire, just complete the form below. This information will not be leased, sold or distributed to third parties by Shire or its representatives. Please read our online privacy policy.

Please send me information about PENTASA and other gastroenterology products from Shire.

All information is required unless noted.

The following statements refer to your opinions about your practice and treatment of Ulcerative Colitis (UC). Please indicate how strongly you agree or disagree with each of the statements using a 1 to 7 scale, where a "1" indicates you "disagree completely with the statement," a "4" indicates you "neither agree nor disagree with the statement," and a "7" indicates you "agree completely with the statement." Please select any number from 1 to 7 to indicate your level of agreement. Select only one answer per row

Strongly
Disagree 		Neither agree nor
disagree 		Strongly
Agree
1 2 3 4 5 6 7
1) I am very often the one introducing my peers to new ideas, techniques, or products.
2) I usually learn about new drugs even before they are approved.
3) Noncompliance with 5-ASAs is a problem among my UC patients.
4) I know my patients won't take their 5-ASAs three times per day so I prescribe 5-ASAs two times per day during remission.
5) I define remission of UC as complete mucosal healing.

Please answer the following question based on the scale of "1" to "3" below.

Given your experience dealing with patients, what percentage of flare-ups is caused by noncompliance?
Low Percentage
0%-25%
1		 Medium Percentage
26%-49%
2		 High Percentage
50%-100%
3

Important Safety Information

  • PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.
  • PENTASA is generally well tolerated. In worldwide clinical trials (N>2100), the most common adverse events were diarrhea (3.4%), headache (2.0%), nausea (1.8%), abdominal pain (1.7%), dyspepsia (1.6%), vomiting (1.5%), and rash (1.0%). As with other mesalamine products, serious adverse events may occur. PENTASA is contraindicated in patients with a hypersensitivity to salicylates. Caution should be used in patients with impaired hepatic or renal function. Patients with pre-existing renal disease, increased BUN or serum creatinine, or proteinuria should be monitored during PENTASA therapy.